Article Text

other Versions

PDF
Regulatory T cells in GI disease and their exploitation in therapy
  1. I L Huibregtse
  1. University of Amsterdam, Netherlands
    1. A U G van Lent
    1. University of Amsterdam, Netherlands
      1. Sander J H van Deventer (deventer{at}xs4all.nl)
      1. University of Amsterdam, Netherlands

        Abstract

        · Activation of mucosal T cells occurs in inflammatory bowel disease and is inhibited by various subsets of "regulatory" T cells, which can be functionally and phenotypically characterized · Regulatory T cells can be generated within the thymus or in peripheral tissues · In mice, a loss of regulatory T cell activity results in inflammatory bowel disease. Regulatory T cell activity has not been thoroughly studied in inflammatory bowel disease, but currently available data do not provide evidence for a loss of regulatory T cell activity in human inflammatory bowel disease · Regulatory T cells can be generated or activated in vivo and in vitro using a variety of approaches, including specific small molecules, cytokine-mediated activation, and gene therapy. These cells have therapeutic activity in the preclinical setting

        • CD4+CD25+
        • IBD
        • Tr1
        • regulatory T-cells
        • therapy

        Statistics from Altmetric.com

        Request permissions

        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.